PGEN - News - Up 20% A.H. | Biotech Message Board Posts


  •  
    As promised, anyone interested can click this link to view the survey results and read some of our initial takeaways from the data collected. Thanks again to all who participated! 

Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  37899 of 38020  at  6/10/2021 5:10:54 PM  by

CHM_760


PGEN - News - Up 20% A.H.

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
- Primary analysis data presented at the Federation of Clinical Immunology Societies (FOCIS) 2021 Virtual Annual Meeting -
- Primary endpoint assessing safety and tolerability met for both Phase 1b monotherapy and Phase 2a combination therapy portions of study -
- AG019, as monotherapy and in combination with teplizumab, showed stabilization of C-peptide levels, a biomarker for T1D disease progression, and induced antigen-specific tolerance in conjunction with the reduction of disease-specific T cell responses -
- Clinical trial assessing the efficacy of prolonged treatment of oral AG019 planned -


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 6     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
37900 Re: PGEN - News - Up 20% A.H. - Now up 38% CHM_760 5 6/10/2021 5:26:08 PM


Financial Market Data provided by
.
Loading...